Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain

European Journal of Pharmacology

Volumn 493, Issue 1-3, 2004, Pages 75-83

  Li, Zhu ^a,b   Ichikawa, Junji ^a   Dai, Jin ^a   Meltzer, Herbert Y ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Psychiatric Hospital at Vanderbilt   (United States)

Author keywords

Antipsychotic; Aripiprazole; Dopamine; Hippocampus; Prefrontal cortex; Serotonin

Indexed keywords

ACETYLCHOLINE; ARIPIPRAZOLE; CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NEUROLEPTIC AGENT;

ANIMAL EXPERIMENT; ARTICLE; BRAIN; COGNITION; CONTROLLED STUDY; DOPAMINE RELEASE; HIPPOCAMPUS; INHIBITION KINETICS; MALE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM; STATISTICAL SIGNIFICANCE;

ACETYLCHOLINE; ANIMALS; ANTIPSYCHOTIC AGENTS; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; HALOPERIDOL; HIPPOCAMPUS; MALE; NUCLEUS ACCUMBENS; PIPERAZINES; PREFRONTAL CORTEX; PYRIDINES; QUINOLONES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A;

EID: 2942551105     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2004.04.028     Document Type: Article

References (43)

1. Amano T., Matsubayashi H., Momiyama T., Ishihara K., Todo N., Sasa M. Antagonizing effects of a novel antipsychotic quinolinone derivative (OPC-14597) on dopaminergic inhibition of neuronal activities in the nucleus accumbens. Prog. Neuro-psychopharmacol. Biol. Psychiatry. 19:1995;105-116
2. Barnes J.M., Barnes N.M., Costall B., Naylor R.J. The actions of (-)N-n-propylnorapomorphine and selective dopamine D1 and D2 receptor agonists to modify the release of [3H]dopamine from the rat nucleus accumbens. Neuropharmacology. 29:1990;327-336
3. 1A receptor activation. Neuropsychopharmacology. 27:2002;430-441
4. Burris K.D., Molski T.F., Xu C., Ryan E., Tottori K., Kikuchi T., Yocca F.D., Molinoff P.B. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Ther. 302:2002;381-389
5. Carson W.H., Kane J.M., Ali M., Dunbar G.C., Ingenito G. Activity of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. Eur. Neuropsychopharmacol. 10:2000;S309
6. Consolo S., Ramponi S., Ladinsky H., Baldi G. A critical role for D1 receptors in the 5-HT1A-mediated facilitation of in vivo acetylcholine release in rat frontal cortex. Brain Res. 707:1996;320-323
7. Eichenbaum H., Dudchenko P., Wood E., Shapiro M., Tanila H. The hippocampus, memory, and place cells: is it spatial memory or a memory space? Neuron. 23:1999;209-226
8. Fernandez G., Klaver P., Fell J., Grunwald T., Elger C.E. Human declarative memory formation: segregating rhinal and hippocampal contributions. Hippocampus. 12:2002;514-519
9. Fujii T., Yoshizawa M., Nakai K., Fujimoto K., Suzuki T., Kawashima K. Demonstration of the facilitatory role of 8-OH-DPAT on cholinergic transmission in the rat hippocampus using in vivo microdialysis. Brain Res. 761:1997;244-249
10. Fujikawa M., Nagashima M., Inoue T., Yamada K., Furukawa T. Partial agonistic effects of OPC-14597, a potential antipsychotic agent, on yawning behavior in rats. Pharmacol. Biochem. Behav. 53:1996;903-909
11. Harvey P.D., Keefe R.S. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am. J. Psychiatry. 158:2001;176-184
12. Ichikawa J., Ishii H., Bonaccorso S., Fowler W.L., O'Laughlin I.A., Meltzer H.Y. 5-HT(2A) and D(2) receptor blockade increases cortical dopamine release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J. Neurochem. 76:2001;1521-1531
13. Ichikawa J., Dai J., Meltzer H.Y. 5-HT(1A) and 5-HT(2A) receptors minimally contribute to clozapine-induced acetylcholine release in rat medial prefrontal cortex. Brain Res. 939:2002;34-42
14. Ichikawa J., Dai J., O'Laughlin I.A., Fowler W.L., Meltzer H.Y. Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology. 26:2002;325-339
15. Ichikawa J., Li Z., Dai J., Meltzer H.Y. Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res. 956:2002;349-357
16. Inoue T., Domae M., Yamada K., Furukawa T. Effects of the novel antipsychotic agent 7-(4-[4-(2, 3-dichlorophenyl)-1-piperazinyl]butyloxy)-3, 4-dihydro-2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. J. Pharmacol.Exp. Ther. 277:1996;137-143
17. Jordan S., Koprivica V., Chen R., Tottori K., Kikuchi T., Altar C.A. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT(1A) receptor. Eur. J. Pharmacol. 441:2002;137-140
18. Kane J.M., Carson W.H., Saha A.R., McQuade R.D., Ingenito G.G., Zimbroff D.L., Ali M.W. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J. Clin. Psychiatry. 63:2002;763-771
19. Kikuchi T., Tottori K., Uwahodo Y., Hirose T., Miwa T., Oshiro Y., Morita S. 7-(4-[4-(2, 3-dichlorophenyl)-1-piperazinyl]butyloxy)-3, 4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J. Pharmacol. Exp. Ther. 274:1995;329-336
20. Kuroki T., Meltzer H.Y., Ichikawa J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J. Pharmacol. Exp. Ther. 288:1999;774-781
21. Laruelle M., Abi-Dargham A., van Dyck C.H., Gil R., D'Souza C.D., Erdos J., McCance E., Rosenblatt W., Fingado C., Zoghbi S.S., Baldwin R.M., Seibyl J.P., Krystal J.H., Charney D.S., Innis R.B. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc. Natl. Acad. Sci. U. S. A. 93:1996;9235-9240
22. Lawler C.P., Prioleau C., Lewis M.M., Mak C., Jiang D., Schetz J.A., Gonzalez A.M., Sibley D.R., Mailman R.B. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology. 20:1999;612-627
23. Liegeois J.F., Ichikawa J., Meltzer H.Y. 5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. Brain Res. 947:2002;157-165
24. Meltzer H.Y. Dopamine D2 receptor occupancy and the action of clozapine: does it make a difference to add a neuroleptic? Biol. Psychiatry. 46:1999;144-149
25. Marona-Lewicka, D.M., Nichols, D.E., 2003. 33rd Annual Neuroscience Meeting, New Orleans, November 12, # 843.18.
26. Meltzer H.Y., McGurk S.R. The effect of clozapine, risperidone and olanzapine on cognitive function in schizophrenia. Schizophr. Bulletin. 25:1999;233-255
27. Millan M.J., Schreiber R., Dekeyne A., Rivet J.M., Bervoets K., Mavridis M., Sebban C., Maurel-Remy S., Newman-Tancredi A., Spedding M., Muller O., Lavielle G., Brocco M. S 16924 ((R)-2-[1-[2-(2, 3-dihydro-benzo[1, 4] dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: II. Functional profile in comparison to clozapine and haloperidol. J. Pharmacol. Exp. Ther. 286:1998;1356-1373
28. Moghaddam B., Bunney B.S. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J. Neurochem. 54:1990;1755-1760
29. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1998;Academic Press, New York
30. Pugsley T.A., Davis M.D., Akunne H.C., MacKenzie R.G., Shih Y.H., Damsma G., Wikstrom H., Whetzel S.Z., Georgic L.M., Cooke L.W. Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907. J. Pharmacol. Exp. Ther. 275:1995;1355-1366
31. 1A receptor activation contributes to ziprasidone-induced dopamine release in the prefrontal cortex. Biol. Psychiatry. 48:2000;229-237
32. Schotte A., Janssen P.F.M., Gommeren W., Luyten W.H.L.M., Van Gompel P., Lesage A.S., De Loore K., Leysen J.E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology. 124:1996;57-73
33. See R.E. Differential effects of 3-PPP enantiomers on extracellular dopamine concentration in the caudate-putamen and nucleus accumbens of rats. Naunyn Schmiedebergs Arch. Pharmacol. 350:1994;605-610
34. Seidman L.G., Kremen W.S., Koren D., Faraone S.V., Goldstein J.M., Tsuang M.T. A comparative profile analysis of neuropsychological functioning in patients with schizophrenia and bipolar psychoses. Schizophr. Res. 53:2002;31-44
35. Semba J., Watanabe A., Kito S., Toru M. Behavioural and neurochemical effects of OPC-14597, a novel antipsychotic drug, on dopaminergic mechanisms in rat brain. Neuropharmacology. 34:1995;785-791
36. Shapiro D.A., Renock S., Arrington E., Chiodo L.A., Liu L.X., Sibley D.R., Roth B.L., Mailman R. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 28:2003;1400-1411
37. Shirazi-Southall S., Rodriguez D.E., Nomikos G.G. Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacology. 26:2002;583-594
38. Stahl S.M. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics: Part 1. "Goldilocks" actions at dopamine receptors. J. Clin. Psychiatry. 62:2001;841-842
39. Stahl S.M. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics: Part 2. Illustrating their mechanism of action. J. Clin. Psychiatry. 62:2001;923-924
40. Volonte M., Monferini E., Cerutti M., Fodritto F., Borsini F. BIMG 80, a novel potential antipsychotic drug: evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex. J. Neurochem. 69:1997;182-190
41. Wilkinson L.O., Middlemiss D.N., Hutson P.H. 5-HT1A receptor activation increases hippocampal acetylcholine efflux and motor activity in the guinea pig: agonist efficacy influences functional activity in vivo. J. Pharmacol. Exp. Ther. 270:1994;656-664
42. William G.V., Goldman-Rakic P.S. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature. 376:1995;572-575
43. Yamada S., Yokoo H., Nishi S. Differential effects of dopamine agonists on evoked dopamine release from slices of striatum and nucleus accumbens in rats. Brain Res. 648:1994;176-179